Biotech Values

[ThomasS]

ANDS/NVS: Speaking of NVS, they still have a collaboration to license ANA 380 (not the recent ANA 975 problem) for HBV if they desire.

Anadys Pharma: Completion of ANA380 dosing in Phase II Clinical trial confirms robust activity against Lamivudine-Resistant Hepatitis B Virus

Co announces will present positive data from an open label, multi-center, dose-escalation Phase II clinical trial of ANA380 in patients with lamivudine-resistant hepatitis B virus infection at the 41st Annual Meeting of the European Association for the Study of the Liver in Vienna, Austria on Thursday, April 27th. Patients treated with ANA380 at 90 mg, 150 mg and 240 mg dose levels experienced reduction in plasma HBV viral DNA at 12 weeks of 3.9 log10, 3.9 log10 and 4.1 log10 units, respectively, (greater than 99.9% clearance of the virus in plasma). Patients treated with ANA380 at 30 mg and 60 mg dose levels experienced comparable reduction in plasma HBV viral DNA at 12 weeks of 2.8 log10 units and 3.2 log10 units, respectively.